Jones Financial Companies Lllp Purchases 44,750 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX)

Jones Financial Companies Lllp boosted its position in shares of Gain Therapeutics, Inc. (NASDAQ:GANX) by 83.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,250 shares of the company’s stock after purchasing an additional 44,750 shares during the quarter. Jones Financial Companies Lllp owned about 0.37% of Gain Therapeutics worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sprott Inc. acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $30,000. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $35,000. Finally, Geode Capital Management LLC grew its position in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the period. 11.97% of the stock is owned by institutional investors.

Gain Therapeutics Price Performance

Shares of GANX opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $1.97. Gain Therapeutics, Inc. has a 52-week low of $0.89 and a 52-week high of $4.63. The firm has a market capitalization of $58.36 million, a PE ratio of -2.00 and a beta of 0.14.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Scotiabank assumed coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 target price for the company. Roth Mkm restated a “buy” rating and set a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Monday, November 25th. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Gain Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.20.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.